-
1
-
-
0017153556
-
Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment
-
Cephalotaxus Research Coordinating Group
-
Cephalotaxus Research Coordinating Group (1976) Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 2(4):263-272
-
(1976)
Chin Med J
, vol.2
, Issue.4
, pp. 263-272
-
-
-
2
-
-
1542753559
-
Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
-
DOI 10.1200/JCO.2003.04.036
-
BD Cheson JM Bennett KJ Kopecky, et al. 2003 Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 24 4642 4649 14673054 10.1200/JCO.2003.04.036 (Pubitemid 46594039)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.24
, pp. 4642-4649
-
-
Cheson, B.D.1
Bennett, J.M.2
Kopecky, K.J.3
Buchner, T.4
Willman, C.L.5
Estey, E.H.6
Schiffer, C.A.7
Doehner, H.8
Tallman, M.S.9
Lister, T.A.10
LoCocco, F.11
Willemze, R.12
Biondi, A.13
Hiddemann, W.14
Larson, R.A.15
Lowenberg, B.16
Sanz, M.A.17
Head, D.R.18
Ohno, R.19
Bloomfield, C.D.20
more..
-
3
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
DOI 10.1182/blood-2005-10-4149
-
BD Cheson PL Greenberg JM Bennett, et al. 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2 419 425 16609072 10.1182/blood-2005-10- 4149 1:CAS:528:DC%2BD28XntFehtrk%3D (Pubitemid 44061337)
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
Lowenberg, B.4
Wijermans, P.W.5
Nimer, S.D.6
Pinto, A.7
Beran, M.8
De Witte, T.M.9
Stone, R.M.10
Mittelman, M.11
Sanz, G.F.12
Gore, S.D.13
Schiffer, C.A.14
Kantarjian, H.15
-
4
-
-
0023096812
-
Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy
-
Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J (1987). Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 87(2):180-186 (Pubitemid 17022456)
-
(1987)
American Journal of Clinical Pathology
, vol.87
, Issue.2
, pp. 180-186
-
-
Delacretaz, F.1
Schmidt, P.-M.2
Piguet, D.3
-
5
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
19230772 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D
-
P Fenaux GJ Mufti E Hellstrom-Lindberg, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 3 223 232 19230772 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D
-
(2009)
Lancet Oncol
, vol.10
, Issue.3
, pp. 223-232
-
-
Fenaux, P.1
Mufti, G.J.2
Hellstrom-Lindberg, E.3
-
6
-
-
28544433130
-
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
-
DOI 10.1038/sj.leu.2403963, PII 2403963
-
U Germing B Hildebrandt M Pfeilstöcker, et al. 2005 Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) Leukemia 19 12 2223 2231 16193087 10.1038/sj.leu.2403963 1:CAS:528:DC%2BD2MXht1ems7nE (Pubitemid 41741618)
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2223-2231
-
-
Germing, U.1
Hildebrandt, B.2
Pfeilstocker, M.3
Nosslinger, T.4
Valent, P.5
Fonatsch, C.6
Lubbert, M.7
Haase, D.8
Steidl, C.9
Krieger, O.10
Stauder, R.11
Giagounidis, A.A.N.12
Strupp, C.13
Kundgen, A.14
Mueller, T.15
Haas, R.16
Gattermann, N.17
Aul, C.18
-
7
-
-
0030897009
-
International scoring system for evaluating prognosis in myelodysplastic syndromes
-
P Greenberg C Cox MM LeBeau, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 6 2079 2088 9058730 1:CAS:528:DyaK2sXhvVars70%3D (Pubitemid 27132124)
-
(1997)
Blood
, vol.89
, Issue.6
, pp. 2079-2088
-
-
Greenberg, P.1
Cox, C.2
LeBeau, M.M.3
Fenaux, P.4
Morel, P.5
Sanz, G.6
Sanz, M.7
Vallespi, T.8
Hamblin, T.9
Oscier, D.10
Ohyashiki, K.11
Toyama, K.12
Aul, C.13
Mufti, G.14
Bennett, J.15
-
8
-
-
0003328595
-
Guidelines for cancer cytogenetics
-
ISCN (International System for Human Cytogenetic Nomenclature) Karger, Basel
-
ISCN (International System for Human Cytogenetic Nomenclature) (1991) Guidelines for cancer cytogenetics. In: Mitelman F (ed) Supplement to an International System for Human Cytogenetic Nomenclature. Karger, Basel, pp 1-53
-
(1991)
Supplement to An International System for Human Cytogenetic Nomenclature
, pp. 1-53
-
-
Mitelman, F.1
-
9
-
-
33746105303
-
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia
-
DOI 10.1038/sj.leu.2404287, PII 2404287
-
J Jin DZ Jiang WY Mai, et al. 2006 Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia Leukemia 20 8 1361 1367 16791270 10.1038/sj.leu.2404287 1:CAS:528:DC%2BD28XntVWksro%3D (Pubitemid 44084048)
-
(2006)
Leukemia
, vol.20
, Issue.8
, pp. 1361-1367
-
-
Jin, J.1
Jiang, D.-Z.2
Mai, W.-Y.3
Meng, H.-T.4
Qian, W.-B.5
Tong, H.-Y.6
Huang, J.7
Mao, L.-P.8
Tong, Y.9
Wang, L.10
Chen, Z.-M.11
Xu, W.-L.12
-
10
-
-
0024518154
-
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia
-
DOI 10.1002/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0. CO;2-V
-
HM Kantarjian MJ Keating RS Walters CA Koller KB McCredie EJ Freireich 1989 Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia Cancer 63 5 813 817 2914287 10.1002/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V 1:STN:280:DyaL1M7hvFeksA%3D%3D (Pubitemid 19063182)
-
(1989)
Cancer
, vol.63
, Issue.5
, pp. 813-817
-
-
Kantarjian, H.M.1
Keating, M.J.2
Walters, R.S.3
Koller, C.A.4
McCredie, K.B.5
Freireich, E.J.6
-
11
-
-
33646071894
-
Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
-
16532500 10.1002/cncr.21792 1:CAS:528:DC%2BD28XksFCrsrk%3D
-
H Kantarjian JP Issa CS Rosenfeld, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 8 1794 1803 16532500 10.1002/cncr.21792 1:CAS:528: DC%2BD28XksFCrsrk%3D
-
(2006)
Cancer
, vol.106
, Issue.8
, pp. 1794-1803
-
-
Kantarjian, H.1
Issa, J.P.2
Rosenfeld, C.S.3
-
12
-
-
33644521267
-
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome
-
16435386 10.1002/cncr.21723
-
H Kantarjian S O'brien J Cortes, et al. 2006 Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome Cancer 106 5 1090 1098 16435386 10.1002/cncr.21723
-
(2006)
Cancer
, vol.106
, Issue.5
, pp. 1090-1098
-
-
Kantarjian, H.1
O'Brien, S.2
Cortes, J.3
-
13
-
-
33845382806
-
Nonparametric estimation from incomplete observation
-
10.2307/2281868
-
E Kaplan P Meier 1958 Nonparametric estimation from incomplete observation J Am Statist Assoc 53 282 457 481 10.2307/2281868
-
(1958)
J Am Statist Assoc
, vol.53
, Issue.282
, pp. 457-481
-
-
Kaplan, E.1
Meier, P.2
-
14
-
-
27244459396
-
Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: A multicenter study of 112 Chinese patients
-
DOI 10.1532/IJH97.A10424
-
JM Li Y Shen DP Wu, et al. 2005 Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients Int J Hematol 82 1 48 54 16105759 10.1532/IJH97.A10424 1:CAS:528:DC%2BD2MXps1KiurY%3D (Pubitemid 41512199)
-
(2005)
International Journal of Hematology
, vol.82
, Issue.1
, pp. 48-54
-
-
Li, J.M.1
Shen, Y.2
Wu, D.P.3
Liang, H.4
Jin, J.5
Chen, F.Y.6
Song, Y.P.7
Wang, J.M.8
Qiu, X.F.9
Hou, M.10
Qiu, Z.C.11
Shen, Z.X.12
-
15
-
-
0042967809
-
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
-
DOI 10.1056/NEJMoa025406
-
B Löwenberg W van Putten M Theobald, et al. 2003 Effect of priming with granulocyte colony stimulating factor on the outcome of chemotherapy for acute myeloid leukemia N Engl J Med 349 8 743 752 12930926 10.1056/NEJMoa025406 (Pubitemid 37010778)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.8
, pp. 743-752
-
-
Lowenberg, B.1
Van Putten, W.2
Theobald, M.3
Gmur, J.4
Verdonck, L.5
Sonneveld, P.6
Fey, M.7
Schouten, H.8
De Greef, G.9
Ferrant, A.10
Kovacsovics, T.11
Gratwohl, A.12
Daenen, S.13
Huijgens, P.14
Boogaerts, M.15
-
16
-
-
79956294708
-
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
-
21483003 10.1200/JCO.2010.30.9245
-
M Lübbert S Suciu L Baila, et al. 2011 Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 15 1987 1996 21483003 10.1200/JCO.2010.30.9245
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
, pp. 1987-1996
-
-
Lübbert, M.1
Suciu, S.2
Baila, L.3
-
17
-
-
16344369386
-
Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells
-
15788130 1:CAS:528:DC%2BD2MXjslCqsLg%3D
-
WY Mai MF Lin 2005 Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells Chin Med J 118 6 487 492 15788130 1:CAS:528:DC%2BD2MXjslCqsLg%3D
-
(2005)
Chin Med J
, vol.118
, Issue.6
, pp. 487-492
-
-
Mai, W.Y.1
Lin, M.F.2
-
18
-
-
75049084540
-
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group
-
20047095 10.1007/s12185-009-0473-4
-
Y Morita A Kanamaru Y Miyazaki, et al. 2010 Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group Int J Hematol 91 1 97 103 20047095 10.1007/s12185-009-0473-4
-
(2010)
Int J Hematol
, vol.91
, Issue.1
, pp. 97-103
-
-
Morita, Y.1
Kanamaru, A.2
Miyazaki, Y.3
-
19
-
-
0036739696
-
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia: Two parallel studies adjusted for various prognostic factors
-
12200672 10.1038/sj.leu.2402591 1:CAS:528:DC%2BD38XmsV2lsbg%3D
-
M Oosterveld P Muus S Suciu, et al. 2002 Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia: two parallel studies adjusted for various prognostic factors Leukemia 16 9 1615 1621 12200672 10.1038/sj.leu.2402591 1:CAS:528:DC%2BD38XmsV2lsbg%3D
-
(2002)
Leukemia
, vol.16
, Issue.9
, pp. 1615-1621
-
-
Oosterveld, M.1
Muus, P.2
Suciu, S.3
-
20
-
-
17744419792
-
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation
-
10846828 1:CAS:528:DC%2BD3cXovVShurg%3D
-
K Saito Y Nakamura M Aoyagi, et al. 2000 Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation Int J Hematol 71 3 238 244 10846828 1:CAS:528:DC%2BD3cXovVShurg%3D
-
(2000)
Int J Hematol
, vol.71
, Issue.3
, pp. 238-244
-
-
Saito, K.1
Nakamura, Y.2
Aoyagi, M.3
-
21
-
-
0037093195
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
-
DOI 10.1200/JCO.2002.04.117
-
LR Silverman EP Demakos BL Peterson, et al. 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 10 2429 2440 12011120 10.1200/JCO.2002.04.117 1:CAS:528:DC%2BD38XksFakur8%3D (Pubitemid 34525728)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.10
, pp. 2429-2440
-
-
Silverman, L.R.1
Demakos, E.P.2
Peterson, B.L.3
Kornblith, A.B.4
Holland, J.C.5
Odchimar-Reissig, R.6
Stone, R.M.7
Nelson, D.8
Powell, B.L.9
DeCastro, C.M.10
Ellerton, J.11
Larson, R.A.12
Schiffer, C.A.13
Holland, J.F.14
-
22
-
-
68949145132
-
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial
-
19528372 10.1200/JCO.2008.19.6550 1:CAS:528:DC%2BD1MXhtFaitrrI
-
DP Steensma MR Baer JL Slack, et al. 2009 Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J Clin Oncol 27 23 3842 3848 19528372 10.1200/JCO.2008.19.6550 1:CAS:528: DC%2BD1MXhtFaitrrI
-
(2009)
J Clin Oncol
, vol.27
, Issue.23
, pp. 3842-3848
-
-
Steensma, D.P.1
Baer, M.R.2
Slack, J.L.3
-
23
-
-
77950076360
-
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia
-
19744710 10.1016/j.leukres.2009.08.010 1:CAS:528:DC%2BC3cXjvFyltLo%3D
-
H Suzushima N Wada H Yamasaki, et al. 2010 Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia Leuk Res 34 5 610 614 19744710 10.1016/j.leukres.2009.08.010 1:CAS:528:DC%2BC3cXjvFyltLo%3D
-
(2010)
Leuk Res
, vol.34
, Issue.5
, pp. 610-614
-
-
Suzushima, H.1
Wada, N.2
Yamasaki, H.3
-
24
-
-
69249219029
-
A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: A single center experience from China
-
19642997 10.1186/1756-8722-2-32 1:CAS:528:DC%2BD1MXhtFCgu7vM
-
J Wang S Lü J Yang, et al. 2009 A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China J Hematol Oncol 2 32 19642997 10.1186/1756-8722-2-32 1:CAS:528:DC%2BD1MXhtFCgu7vM
-
(2009)
J Hematol Oncol
, vol.2
, pp. 32
-
-
Wang, J.1
Lü, S.2
Yang, J.3
-
25
-
-
0028942481
-
Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: A pilot study
-
7531259 1:STN:280:DyaK2M7kslClug%3D%3D
-
K Yamada S Furusawa K Saito, et al. 1995 Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study Leukemia 9 1 10 14 7531259 1:STN:280:DyaK2M7kslClug%3D%3D
-
(1995)
Leukemia
, vol.9
, Issue.1
, pp. 10-14
-
-
Yamada, K.1
Furusawa, S.2
Saito, K.3
|